Global Next Generation Cancer Diagnostics Market Research and Forecast, 2019-2025
|発行||Orion Market Research Pvt Ltd||商品コード||801135|
|次世代型がん診断の世界市場の分析と予測 Global Next Generation Cancer Diagnostics Market Research and Forecast, 2019-2025|
|出版日: 2019年03月06日||ページ情報: 英文||
当レポートでは、世界の次世代型がん診断の市場の現状と見通しについて分析し、診断手法の概要や市場の基本構造、外部からのマクロ的・ミクロ的影響、主な促進・抑制要因、世界全体および地域別の市場動向の見通し (今後6年間分)、セグメント別 (技術、用途、エンドユーザーなど) の詳細動向、最新の市場競争状況、主要企業のプロファイルなどを調査しております。
Global Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report by Technology (Next Generation Sequencing, QPCR & Multiplexing, Protein Microarrays, DNA Microarrays, and Others), by Application (Biomarker Development, Proteomic Analysis, Cancer Screening, and Others) by End-User (Hospital & Clinics, and Research Centers), and Forecast, 2019-2025
Next generation cancer diagnostics technology offers potential in the discovery of advanced actionable targets for cancer. This technique is more sensitive and provides effective diagnostic solutions in cancer as compared to Sanger sequencing. In the next generation sequencing, multiple anomalies consisting of different genomic scales can be assayed simultaneously. The technology is actively used in various applications, including proteomic analysis, cancer screening, and biomarker development, among others.
Increase in government initiatives for the development of advanced technologies in cancer diagnostics is driving the growth of the market. The rising prevalence of cancer disorders across the globe is offering a growth opportunity for the market. According to the National Cancer Institute (the US), in 2018, around 2 million cases of cancer were diagnosed in the US, among which, nearly 609,640 mortality cases were estimated in the country due to cancer. The rising development of advanced next-generation cancer diagnostic technologies is expected to cater to the increasing number of cancer patients across the globe.
Global next generation cancer diagnostics market is further analyzed on the basis of geography, including North America, Europe, Asia-Pacific, and Rest of the World. North America contributed the largest share in the global next-generation cancer diagnostics market in 2018. This is mainly owing to the increasing prevalence of cancer in the region, owing to which, there are favorable investments being provided by the government for the development of advanced diagnostics and therapeutics. Asia-Pacific is projected to exhibit the fastest growth in the global next-generation cancer diagnostics market during the forecast period. The rising medical tourism and increasing focus on the establishment of advanced healthcare infrastructure in emerging economies such as India and China are some factors that are propelling the market growth in the region.
Major market players operating in the global next-generation cancer diagnostics market include Agilent Technologies, Inc., Biospherex LLC, F. Hoffmann-La Roche Ltd, General Electric Co., Illumina, Inc., Novartis AG, and PerkinElmer Inc., among others. These companies adopt various strategies such as geographical expansion, merger & acquisition, partnership & collaborations, finding a new market or innovations in their core competency in order to stay competitive in the market.
The market study of the global next-generation cancer diagnostics market is incorporated by extensive primary and secondary research conducted by a research team at OMR. Secondary research has been conducted to refine the available data to break down the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.
The report is intended for biotechnology companies, research organizations, investment companies, government organizations for overall market analysis and competitive analysis. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.